Continuing Education Online - Free CE/CME

Retina Resource

30th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma - Learning Hub

Stay up to date with the latest advances in hematologic malignancies throug…

23rd Annual School of Breast Oncology® Curriculum

Joyce O’Shaughnessy, MD

Cases and Conversations®: Advancing Diagnosis and Long-Term Management of CIDP

Karissa Gable, MD; Jeffrey Allen, MD; Suraj Muley, MD, FAAN

Live Tumor Board: Translating Biomarker Insights and Therapeutic Advances Into Endometrial Cancer Practice

Kathleen N. Moore, MD, MS, FASCO; Ritu Salani, MD, MBA; Casey Cosgrove, MD;…

Primary Care Playbook: Advancing COVID-19 Prophylaxis in Community Practice

Chuck Vega, MD; Stefan Gravenstein MD, MPH

Tumor Board: Clinical Integration of Molecular Profiling in Glioma—Transforming the Use of Targeted Therapy

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Ashley S. Margol, MD, M…

Cases and Conversations™: Redefining Treatment Pathways in Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, MD; David M. Gershenson, MD; Ursula Matulonis, MD; David…

Community Practice Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma

Lori A. Leslie, MD; Krish Patel, MD

Advancing Presbyopia Care: Patient-Centered Strategies for Pharmacologic Management

Brian Szabo, DO; Nick Bruns, OD, FAAO

PER® Postgame™: Addressing the Unmet Medical Needs of Patients with Psoriasis—Summarizing the Latest Advancements in Oral Therapy

Jason E. Hawkes, MD, MS; Christopher G. Bunick, MD, PhD

Searching for Silence: Corneal Sensitivity Testing in NK

Francis Mah, MD; Amy Nau, OD , FAAO, Dipl. CCLRT

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Seth A. Wander, MD, PhD; Yang Liu, MD

From Data to Decisions: Applying the Latest Evidence for New Targeted Therapies in HER2-Positive Gastroesophageal Adenocarcinoma

Pashtoon Kasi, MD, MS; Elizabeth Conner, MD; Simona De Michele, MD

From Numbers to Navigation: Translating Data From Diabetes Technologies into Optimized Decision-Making

Diana Isaacs, PharmD, BCACP, CDCES, BC-ADM, FADCES, FCCP; Robert H. Eckel, …

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Solange Peters, MD, PhD; Benjamin P. Levy, MD; Tony S.K. Mok, MD, BMSc, FRC…

Live Tumor Board: Multidisciplinary Strategies to Prevent and Manage ADC-Associated Pulmonary Toxicities in Ovarian Cancer

Kathleen N. Moore, MD, MS, FASCO; Rachel N. Grisham, MD; Rohit Gupta, MD; M…

Rapid Reviews in Retina™: Emerging Updates from Winter 2026 – Addressing the Wealth of New Data in Treatments for nAMD, DME, and RVO

Judy E. Kim, MD, FARVO, FASRS; Prethy Rao, MD, MPH, FACS

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Marla D. Lipsyc-Sharf, MD; Richard Zelkowitz, MD

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Seth A. Wander, MD, PhD; Ruta D. Rao, MD

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Seth A. Wander, MD, PhD; Kate Baxstrom, MD

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – North Carolina

Girish Kunapareddy, MD; Sara M. Tolaney, MD, MPH

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Wyoming & Montana

Yan Ji, MD; Neil M. Iyengar, MD

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Washington

Alison K. Conlin, MD; Neil M. Iyengar, MD

Show Me the Data®: From Mutation to Action — KRAS as a Therapeutic Target in PDAC

E. Gabriela Chiorean, MD; Tanios S. Bekaii-Saab, MD; Mitesh Borad, MD; Chri…

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice Society

Seth A. Wander, MD, PhD; Kamel Abou Hussein, MD

Optimizing HER2 Testing in Gastroesophageal Adenocarcinoma: Laying the Foundation for Targeted Therapy

Yelena Y. Janjigian, MD; Michal F. Segal, BSN, OCN

Next Generation Therapies in AML: Menin Inhibitors, IDH1/2, Combinations, Maintenance, and Beyond! – Arizona

Naval G. Daver, MD; Matthew Ulrickson, MD

Optimizing Diagnosis for Patients with Chronic Idiopathic Constipation

Carmen Fong, MD

Clinical Crossroads™: Delayed Identification of Hypercortisolism – What Are the Risks?

Yehuda Handelsman, MD, FACP, FNLA, FASPC, FAHA, MACE

11th Annual School of Gastrointestinal Oncology®

E. Gabriela Chiorean, MD; Anthony El-Khoueiry, MD

Show Me the Data®: Evolving Standards and New Frontiers in Ovarian Cancer

Ursula A. Matulonis, MD; Bradley J. Monk, MD, FACS, FACOG; Ritu Salani, MD,…

Oncology Town Hall: Translating the Latest Updates Into the Care of Patients With AML in Community Practice

Eunice Wang, MD; Hetty Carraway, MD, MBA; Naval G. Daver, MD

Cases and Conversations™: Integrating PSMA-Directed Radioligand Therapy in Prostate Cancer Care: Recent Data and Evolving Strategies

Mary-Ellen Taplin, MD; Jeremie Calais, MD, PhD; Himanshu Nagar, MD, MS

Lupus Nephritis Postgame: Takeaways from our Expert Faculty

Shivani Garg, MD, PhD; Samir V. Parikh, MD, FASN

Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Christine M. Lovly, MD, PhD, FASCO; Xiuning Le, MD, PhD; Hossein Borghaei, …

Medical Crossfire® — From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

David S. Klimstra, MD; Danielle A. Hutchings, MD; Nancy M. Joseph, MD, PhD;…

19th Annual New York GU Cancers Congress®

Maha Hussain, MD, FACP, FASCO; Daniel P. Petrylak, MD

Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer

Sanja Dacic, MD, PhD; Soo-Ryum (Stewart) Yang, MD; Isabel Preeshagul, DO, M…

Community Practice Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer

Neil M. Iyengar, MD; Sara M. Tolaney, MD, MPH

Burst CME Expert Illustrations & Commentaries™: Breaking Down DLL3-Targeting Immune Cell Effector Agents in SCLC

Jacob Sands, MD; Anne Chiang, MD, PhD

Collaborating Across the Continuum®: Tying the Threads: Screening, Referrals, and Optimized Treatments in MASLD/MASH

Nancy Reau, MD; Conan Tu, MD; Sonal Kumar, MD, MPH

Publication Review: Defining On-Treatment Remission in Plaque Psoriasis

April W. Armstrong, MD, MPH; Tina Bhutani-Jacques MD

Virtual Hot Seat: How the Experts Target the PI3K/AKT/mTOR Pathway in HR+/HER2– Metastatic Breast Cancer

Rebecca Shatsky, MD; Maxwell Roger Lloyd, MD; Sarah Sammons, MD; Sherry She…

How Do I Identify MOGAD? Improving Outcomes Through Early Identification of Patients

Michael Levy, MD, PhD; Jeffrey L. Bennett, MD, PhD; Eoin P. Flanagan, MB, B…

Medical Crossfire®: Translating Risk into Action—Redefining Adjuvant Strategies for Early HR+/HER2– Breast Cancer

Ann H. Partridge, MD, MPH; William J. Gradishar, MD, FASCO, FACP; Saranya C…

OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2- Breast Cancer

Joyce O’Shaughnessy, MD; Virginia Kaklamani, MD, DSc; Seth A. Wander, MD, P…

Cases and Conversations: Translating ctDNA Into Clinical Decisions in Breast Cancer

Neil M. Iyengar, MD; Kelly Elizabeth McCann, MD, PhD; Wassim Mchayleh, MD, …